Apnimed的新睡前安眠药丸显示效果可喜, 将严重性降低近50%, Apnimed's new pill for sleep apnea shows promising results, reducing severity by nearly 50%.

制药公司Apnimed Inc.报告其第三阶段对AD109的临床试验取得了积极成果,AD109是阻塞睡眠动脉的口服药(OSA)。 Pharmaceutical company Apnimed Inc. has reported positive results from its stage III clinical trial for AD109, an oral pill for obstructive sleep apnea (OSA). 该药丸增加了上呼吸道肌肉的音调,表明OSA严重性下降近50%,而安慰剂组为6.8%。 The pill, which increases upper airway muscle tone, showed a nearly 50% reduction in OSA severity compared to 6.8% in the placebo group. 约23%的参与者实现了完全的疾病控制。 About 23% of participants achieved complete disease control. 由于两项大型研究均显示出有效性,Apnimed计划在2026年初申请FDA批准. With consistent efficacy demonstrated in two large studies, Apnimed plans to seek FDA approval in early 2026.